DOI: 10.36347/sjams.2016.v04i10.043

Pages: 3773-3775

Gram-negative bacilli (GNB) are commonly implicated in clinical diseases. However, with their increasing resistance to antimicrobial agents, treatment becomes a challenge. The increasing frequency and antibiotic resistance among extended-spectrum β-lactamases (ESBLs)-producing bacteria are posing a serious threat. ESBL producers most often acquire and exhibit additional resistance to other antimicrobials such as Quinolones, Cotrimoxazole, Trimethoprim, Tetracycline’s and Aminoglycosides, thus making the therapeutic options very limited. The present study was conducted in a tertiary care hospital from Jan2016-June2016. ESBL screening was done as per Clinical Laboratory Standards Institute (CLSI) guidelines. A total of 889 urinary isolates were included in the study, of which 368 were Klebsiella pneumoniae and 195 Were Escherichia coli, these were subjected for ESBL screening by Kirby-Bauer method and confirmed by Disk potentiation method & Double Disc synergy method and 34% of Klebsiella pneumoniae & 45% of E.coli were found to be ESBL producers. Imipenem susceptibility was 100%. Over 90% of ESBL isolates showed resistance to Aztreonam and Cephalosporins .Resistance to Aminoglycosides and Quinolones was relatively low. Imipenem should be reserved for life threatening infections. Periodic susceptibility studies will help the physicians in choosing empirical therapy and preserve the higher antimicrobials to life threatening infections.